PT - JOURNAL ARTICLE AU - T.-W. Lee AU - J.E. Park AU - David Hung TI - Gaussian Statistics and Data-Assimilated Model of Mortality due to COVID-19: China, USA, Italy, Spain, UK, Iran, and the World Total AID - 10.1101/2020.04.06.20055640 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.06.20055640 4099 - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055640.short 4100 - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055640.full AB - Covid-19 is characterized by rapid transmission and severe symptoms, leading to deaths in some cases (ranging from 1.5 to 12% of the affected, depending on the country). We identify the Gaussian nature of mortality due to covid-19, as shown in China where it appears to have run its course (during the first sweep of the pandemic at least) and other coutnries, and also in Imperial College modeling. Gaussian distribution involves three parameters, the height, peak location and the width, and the streaming data can be used to infer function value, slope and inflection location as a minimum set of constraints to estimate the subsequent trajectories. Thus, we apply the Gaussian function template as the basis for a data-assimilated model of covid-19 trajectories, first to USA, United Kingdom (UK), Iran and the world total in this study. As more data become available, the Gaussian trajectories are updated, for other nations and also for state-by-state projections in USA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was applicable for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data have been obtained from a public source (Ref 1). Our own analysis data are available upon request (attwl@asu.edu), and will be posted online after a website is set up.